---

Stem Cells: Transplant Surgery

Answer

NHS England does not routinely collect or hold data on the number of patients with blood cancer who do not meet the eligibility criteria set out in its clinical commissioning policies, the numbers who have not been funded to receive treatment under the current commissioning policy, or the number of patients whose disease relapsed under 12 months of a first allogeneic-hematopoietic stem cell transplant.

NHS England recognises the seriousness of relapse following a stem cell transplant and is actively reviewing the current policy, working with clinicians, patients, and charities to assess the latest available evidence. A revised draft policy is expected to undergo stakeholder testing in the new year, with final decisions currently anticipated in late spring 2027.

The ongoing review will consider the latest peer-reviewed clinical evidence, alongside clinical benefit, patient safety, affordability, and the opportunity cost of any new investment. Any changes to commissioning arrangements will be considered through NHS England's established policy development process, which includes an independent evidence review, expert clinical input, patient and public involvement, and stakeholder testing. Stakeholders will have the opportunity to comment on the draft policy through a formal stakeholder testing process before any final decisions are made.

Secondary information

Type

Written question

Reference

19836

Session

2026-27

Grouped for answer

Yes

Subjects

Transplant surgery Stem cells Blood cancer

Contains statistics

Yes

Link

View this Written question on www.parliament.uk